UPS invests $48 million in 27 temperature-controlled facilities for healthcare logistics

UPS Invests $48 Million to Expand Cold-Chain Network for Pharmaceuticals

United Parcel Service is investing $48 million in 27 temperature-controlled facilities across the Americas, Europe, and Asia. The move is designed to enhance the company's cold-chain capabilities for pharmaceuticals and biologics, improving speed and ensuring a complete, end-to-end chain of custody for shipments that require strict temperature management.

"These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes."
— UPS Healthcare President John Bolla

The expansion aims to ensure that critical, temperature-sensitive treatments are delivered safely and reliably to patients around the world. Kate Gutmann, UPS president of international, healthcare and supply chain solutions, stated that the new global cross-dock facilities "strengthen our end-to-end cold-chain capabilities."

Healthcare remains one of UPS's top priorities and biggest areas of growth. CEO Carol Tomé noted on the company's first-quarter earnings call in April that UPS's global healthcare portfolio has gained market share every year since 2021. The company also generated its first $3 billion healthcare revenue quarter in Q1 2024.

The investment comes as the market for temperature-sensitive biologics is expanding rapidly. According to Growth Market Reports, demand is projected to grow at an 8.3% compound annual growth rate through 2033, reaching a market value of approximately $39.1 billion.

The need for reliable cold-chain logistics is critical. The World Health Organization estimates that up to 50% of global vaccines are wasted every year, partly due to cold-chain storage issues.

The rise of GLP-1 drugs, such as Novo Nordisk's Wegovy and Ozempic, which require strict refrigeration, has further intensified the focus on temperature-controlled logistics. These investments reflect a strategic response to a market where reliable cold chain infrastructure is directly tied to patient outcomes and the reduction of medical waste.